Please Wait.....
Report
Castrate-Resistant Prostate Cancer Market Report and Forecast 2024-2032
Market Report I 2023-09-12 I 200 Pages I EMR Inc.
Castrate Resistant Prostate Cancer Market Report and Forecast 2024-2032
Castrate Resistant Prostate Cancer Market Outlook
The castrate resistant prostate cancer market was valued at USD 11.2 billion in 2023, driven by increasing collaboration among pharmaceutical companies. The market size is anticipated to grow at a CAGR of 8.7% during the forecast period of 2024-2032 to achieve a value of USD 23.5 billion by 2032.
Castrate Resistant Prostate Cancer: Introduction
Castration-resistant prostate cancer (CRPC) is a form of prostate cancer that no longer responds to medical or surgical interventions that lower testosterone levels in the body, such as surgical castration (removal of the testicles) or androgen deprivation therapy (ADT). Testosterone is a male hormone that can stimulate the growth of prostate cancer cells. When prostate cancer becomes resistant to these therapies, it can continue to grow and spread even in the absence of testosterone.
Key Trends in the Global Castrate Resistant Prostate Cancer Market
The castrate resistant prostate cancer market has been experiencing significant growth and evolution in recent years. Several key trends are some key trends shaping the market:
- Emerging Therapies: New therapeutic options, including novel androgen receptor-targeted therapies, immunotherapies, and radiopharmaceuticals, are continuing to emerge. These treatments aim to provide improved efficacy and fewer side effects for CRPC patients.
- Biomarker-Driven Treatment: Personalized medicine approaches are gaining prominence. Biomarker testing helps identify specific genetic mutations or protein markers that guide treatment decisions, ensuring patients receive therapies tailored to their unique molecular profiles.
- Immunotherapy Advancements: Immune checkpoint inhibitors and other immunotherapies are being explored for their potential in treating CRPC. These therapies aim to harness the patient's immune system to target cancer cells.
- Radiopharmaceuticals: Radiopharmaceuticals such as radium-223 (Xofigo) have been approved for the treatment of CRPC patients with bone metastases. This trend continues to evolve with the development of new agents.
- Combination Therapies: Researchers and pharmaceutical companies are investigating combination therapies that target multiple pathways involved in CRPC simultaneously. This approach aims to enhance treatment efficacy and delay disease progression.
Castrate Resistant Prostate Cancer Market Segmentations
The market can be categorized into therapy type, therapy drug class, route of administration, distribution channel, and region.
Market Breakup by Therapy Type
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- Others
Market Breakup by Therapy Drug Class
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Market Breakup by Region -7MM
- United States
- EU-4 and the United Kingdom
- Japan
Castrate Resistant Prostate Cancer Market Overview
The market for Castrate Resistant Prostate Cancer (CRPC) continues to be a significant and evolving aspect of the oncology landscape. CRPC, a stage of prostate cancer that no longer responds to hormone therapy, has seen notable advancements in diagnosis and treatment. Innovative therapies, including next-generation anti-androgens and immunotherapies, have been approved and are offering new hope to patients with CRPC. Additionally, molecular profiling and precision medicine approaches are gaining prominence in tailoring treatments to individual patients, enhancing their efficacy, and reducing side effects. Clinical trials are ongoing, exploring novel therapeutic modalities, combination therapies, and biomarker-driven interventions. The CRPC market remains dynamic, with a focus on improving patient outcomes, enhancing the quality of life, and extending survival for those affected by this challenging form of cancer. Collaboration among pharmaceutical companies, research institutions, and healthcare providers plays a pivotal role in advancing CRPC treatment options.
Key Players in the Castrate Resistant Prostate Cancer Market
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the castrate resistant prostate cancer market are as follows:
- Sanofi
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Astellas Pharma, Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Novartis AG
- Eli Lilly and Company
- Merck & Co., Inc.
- Allergan
- AstraZeneca
- Cipla Inc.
- Amneal Pharmaceuticals LLC
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1Preface
1.1Objectives of the Study
1.2Key Assumptions
1.3Report Coverage - Key Segmentation and Scope
1.4Research Methodology
2Executive Summary
3Castrate-Resistant Prostate Cancer Overview
3.1Guidelines and Stages
3.2Pathophysiology
3.3Screening and Diagnosis
3.4Treatment Pathway
4Patient Profile
4.1Patient Profile Overview
4.2Patient Psychology and Emotional Impact Factors
4.3Risk Assessment and Treatment Success Rate
5Castrate-Resistant Prostate Cancer Epidemiology Analysis-7MM
5.1Epidemiology Overview (2017-2032)
5.2United States Castrate-Resistant Prostate Cancer Epidemiology (2017-2032)
5.3EU-4 and United Kingdom Castrate-Resistant Prostate Cancer Epidemiology (2017-2032)
5.4Japan Castrate-Resistant Prostate Cancer Epidemiology (2017-2032)
6 Castrate-Resistant Prostate Cancer Market Overview
6.1 Castrate-Resistant Prostate Cancer Market Historical Value (2017-2023)
6.2 Castrate-Resistant Prostate Cancer Market Forecast Value (2024-2032)
7 Castrate-Resistant Prostate Cancer Market Landscape
7.1Castrate-Resistant Prostate Cancer: Developers Landscape
7.1.1Analysis by Year of Establishment
7.1.2Analysis by Company Size
7.1.3Analysis by Region
7.2Castrate-Resistant Prostate Cancer: Product Landscape
7.2.1Analysis by Therapy Type
7.2.2Analysis by Drug Class
7.2.3Analysis by Route of Administration
8Castrate-Resistant Prostate Cancer Challenges and Unmet Needs
8.1Treatment Pathway Challenges
8.2Compliance and Drop-Out Analysis
8.3Awareness and Prevention Gaps
9Cost of Treatment
10 Castrate-Resistant Prostate Cancer Market Dynamics
10.1Market Drivers and Constraints
10.2SWOT Analysis
10.3Porter's Five Forces Model
10.4Key Demand Indicators
10.5Key Price Indicators
10.6Industry Events, Initiatives, and Trends
10.7Value Chain Analysis
11 Castrate-Resistant Prostate Cancer Market Segmentation
11.1 Castrate-Resistant Prostate Cancer Market by Therapy Type
11.1.1Market Overview
11.1.2Hormonal Therapy
11.1.3Immunotherapy
11.1.4Chemotherapy
11.1.5Others
11.2 Castrate-Resistant Prostate Cancer Market by Therapy Drug Class
11.2.1Market Overview
11.2.2Antineoplastic
11.2.3Non-steroidal Antiandrogen
11.2.4Corticosteroids
11.2.5Others
11.3 Castrate-Resistant Prostate Cancer Market by Route of Administration
11.3.1Market Overview
11.3.2Oral
11.3.3Parenteral
11.4 Castrate-Resistant Prostate Cancer Market by Distribution Channel
11.4.1Market Overview
11.4.2Hospital Pharmacy
11.4.3Retail Pharmacy
11.4.4Online Pharmacy
11.5 Castrate-Resistant Prostate Cancer Market by Region -7MM
11.5.1Market Overview
11.5.2United States
11.5.3EU-4 and the United Kingdom
11.5.4Japan
12United States Castrate-Resistant Prostate Cancer Market
12.1U.S. Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)
12.2U.S. Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)
12.3Market Size by Therapeutic Class
13EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market
13.1EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)
13.2EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)
13.3Market Size by Therapeutic Class
14Japan Castrate-Resistant Prostate Cancer Market
14.1Japan Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)
14.2Japan Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)
14.3Market Size by Therapeutic Class
15Regulatory Framework
15.1Regulatory Overview
15.1.1US FDA
15.1.2EU EMA
15.1.3JAPAN PMDA
16Patent Analysis
16.1Analysis by Type of Patent
16.2Analysis by Publication year
16.3Analysis by Issuing Authority
16.4Analysis by Patent Age
16.5Analysis by CPC Analysis
16.6Analysis by Patent Valuation
16.7Analysis by Key Players
17Grants Analysis
17.1Analysis by year
17.2Analysis by Amount Awarded
17.3Analysis by Issuing Authority
17.4Analysis by Grant Application
17.5Analysis by Funding Institute
17.6Analysis by NIH Departments
17.7Analysis by Recipient Organization
18Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2Analysis by Trial Status
18.3Analysis by Trial Phase
18.4Analysis by Therapeutic Area
18.5Analysis by Geography
19Funding and Investment Analysis
19.1Analysis by Funding Instances
19.2Analysis by Type of Funding
19.3Analysis by Funding Amount
19.4Analysis by Leading Players
19.5Analysis by Leading Investors
19.6Analysis by Geography
20Partnership and Collaborations Analysis
20.1Analysis by Partnership Instances
20.2Analysis by Type of Partnership
20.3Analysis by Leading Players
20.4Analysis by Geography
21Supplier Landscape
21.1Sanofi
21.1.1Financial Analysis
21.1.2Product Portfolio
21.1.3Demographic Reach and Achievements
21.1.4Mergers and Acquisitions
21.1.5Certifications
21.2Johnson & Johnson Services Inc.
21.2.1Financial Analysis
21.2.2Product Portfolio
21.2.3Demographic Reach and Achievements
21.2.4Mergers and Acquisitions
21.2.5Certifications
21.3Pfizer Inc.
21.3.1Financial Analysis
21.3.2Product Portfolio
21.3.3Demographic Reach and Achievements
21.3.4Mergers and Acquisitions
21.3.5Certifications
21.4Astellas Pharma, Inc.
21.4.1Financial Analysis
21.4.2Product Portfolio
21.4.3Demographic Reach and Achievements
21.4.4Mergers and Acquisitions
21.4.5Certifications
21.5Bayer AG
21.5.1Financial Analysis
21.5.2Product Portfolio
21.5.3Demographic Reach and Achievements
21.5.4Mergers and Acquisitions
21.5.5Certifications
21.6F. Hoffmann-La Roche Ltd.
21.6.1Financial Analysis
21.6.2Product Portfolio
21.6.3Demographic Reach and Achievements
21.6.4Mergers and Acquisitions
21.6.5Certifications
21.7Mylan N.V.
21.7.1Financial Analysis
21.7.2Product Portfolio
21.7.3Demographic Reach and Achievements
21.7.4Mergers and Acquisitions
21.7.5Certifications
21.8Teva Pharmaceutical Industries Ltd.
21.8.1Financial Analysis
21.8.2Product Portfolio
21.8.3Demographic Reach and Achievements
21.8.4Mergers and Acquisitions
21.8.5Certifications
21.9GlaxoSmithKline plc
21.9.1Financial Analysis
21.9.2Product Portfolio
21.9.3Demographic Reach and Achievements
21.9.4Mergers and Acquisitions
21.9.5Certifications
21.10Novartis AG
21.10.1Financial Analysis
21.10.2Product Portfolio
21.10.3Demographic Reach and Achievements
21.10.4Mergers and Acquisitions
21.10.5Certifications
21.11Eli Lilly and Company
21.11.1Financial Analysis
21.11.2Product Portfolio
21.11.3Demographic Reach and Achievements
21.11.4Mergers and Acquisitions
21.11.5Certifications
21.12Merck & Co., Inc.
21.12.1Financial Analysis
21.12.2Product Portfolio
21.12.3Demographic Reach and Achievements
21.12.4Mergers and Acquisitions
21.12.5Certifications
21.13Allergan
21.13.1Financial Analysis
21.13.2Product Portfolio
21.13.3Demographic Reach and Achievements
21.13.4Mergers and Acquisitions
21.13.5Certifications
21.14AstraZeneca
21.14.1Financial Analysis
21.14.2Product Portfolio
21.14.3Demographic Reach and Achievements
21.14.4Mergers and Acquisitions
21.14.5Certifications
21.15Cipla Inc.
21.15.1Financial Analysis
21.15.2Product Portfolio
21.15.3Demographic Reach and Achievements
21.15.4Mergers and Acquisitions
21.15.5Certifications
21.16Amneal Pharmaceuticals LLC
21.16.1Financial Analysis
21.16.2Product Portfolio
21.16.3Demographic Reach and Achievements
21.16.4Mergers and Acquisitions
21.16.5Certifications
22Castrate-Resistant Prostate Cancer - Distribution Model (Additional Insight)
22.1Overview
22.2Potential Distributors
22.3Key Parameters for Distribution Partner Assessment
23Key Opinion Leaders (KOL) Insights (Additional Insight)
24Company Competitiveness Analysis (Additional Insight)
24.1Very Small Companies
24.2Small Companies
24.3Mid-Sized Companies
24.4Large Companies
24.5Very Large Companies
25Payment Methods (Additional Insight)
25.1Government Funded
25.2Private Insurance
25.3Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security